Grace Therapeutics, Inc.

Grace Therapeutics, Inc. (ticker: GRCE) is an NASDAQ-listed pharmaceutical preparations company. DredgeCap's structured extraction of GRCE's SEC filings surfaces 2 active risk signals, including 2 auditor-change signals. GRCE reported $100.00M in revenue and -$6.62M for the period ending 2022-03-31, with operating cash flow of -$7.17M. Cash and equivalents stood at $18.67M (up 68.9% year-over-year). Total assets of $68.49M exceed total liabilities of $3.60M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

GRCE Cash Runway

Months-of-runway analysis for GRCE, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on GRCE

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.